Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

US biotech Sage Therapeutics on Friday sued Biogen, a week after the biotech giant made an unsolicited offer to acquire the smaller neuroscience company for about $469 million, according to a ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum ...

Sage Therapeutics’ shares jumped over 45% to $8.09 in after-hours on Friday, after the company confirmed that biotech major ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...